Skip to search formSkip to main contentSkip to account menu

refractory hairy cell leukemia

Known as: Hairy Cell Leukemia, Refractory, leukemia, hairy cell, recurrent, recurrent hairy cell leukemia 
Hairy cell leukemia that is resistant to treatment.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Moxetumomab pasudotox-tdfk is a first-in-class recombinant CD22-directed cytotoxin approved in the US for the treatment of adult… 
2018
2018
7060Background: Moxe is an immunotoxin targeting CD22 on B cells leading to cell death. The objectives of this analysis were to… 
2014
2014
Hairy cell leukemia is a rare chronic lymphoproliferative disorder with indolent but progressive clinical course. Patients… 
2012
2012
In Journal of Clinical Oncology, Kreitman et al report the efficacy of anti-CD22 monoclonal antibody (mAb) conjugated to… 
Review
2011
Review
2011
Standard treatment for hairy cell leukemia (HCL) is markedly effective, but the constant decrease in disease-free survival… 
2010
2010
Abstract 2516 Currently no adequate therapies exist for patients with refractory hairy cell leukemia (HCL). The CD22 antigen is… 
2005
2005
A 69-year-old man was referred to our hospital because of thrombocytopenia and was diagnosed as having hairy cell leukemia… 
2004
2004
We report the case of a 76-year-old man with hairy cell leukemia (HCL)-Japanese variant who underwent rituximab therapy. HCL…